Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy.
about
Emerging concepts in the immunopathogenesis of AIDSInefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivoBiologically-directed modeling reflects cytolytic clearance of SIV-infected cells in vivo in macaquesAnalysis of successful immune responses in persons infected with hepatitis C virusHighly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: analysis of cellular immune responsesStrong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removalDendritic cells reveal a broad range of MHC class I epitopes for HIV-1 in persons with suppressed viral load on antiretroviral therapyDirectly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latencyAntigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cellsEfficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialDynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabineImpact of highly active antiretroviral therapy initiation on CD4(+) T-cell repopulation in duodenal and rectal mucosa.No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy.Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatmentAnti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiencyDifferential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children.Processing and presentation of exogenous HLA class I peptides by dendritic cells from human immunodeficiency virus type 1-infected persons.Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motifRelative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA allelesLimited sequence evolution within persistently targeted CD8 epitopes in chronic human immunodeficiency virus type 1 infection.Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy.In vitro human immunodeficiency virus eradication by autologous CD8(+) T cells expanded with inactivated-virus-pulsed dendritic cells.Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals.Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells.Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assayWeak anti-HIV CD8(+) T-cell effector activity in HIV primary infectionThe most common Chinese rhesus macaque MHC class I molecule shares peptide binding repertoire with the HLA-B7 supertype.MHC class II genotype and the control of viremia in HIV-1-infected individuals on highly active antiretroviral therapy.Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.Effect of zidovudine on the primary cytolytic T-lymphocyte response and T-cell effector function.CD8(+) T-cell gamma interferon production specific for human immunodeficiency virus type 1 (HIV-1) in HIV-1-infected subjectsTransient antiretroviral treatment during acute simian immunodeficiency virus infection facilitates long-term control of the virus.Correlates of cytotoxic T-lymphocyte-mediated virus control: implications for immunosuppressive infections and their treatmentPersistence of genital tract T cell responses in HIV-infected women on highly active antiretroviral therapy.Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells.Two types of cytotoxic lymphocyte regulation explain kinetics of immune response to human immunodeficiency virusResidual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection.Induction of anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) and CD4(+) T-cell reactivity by dendritic cells loaded with HIV-1 X4-infected apoptotic cells.Protective antigen-independent CD8 T cell memory is maintained during {gamma}-herpesvirus persistenceTherapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a Phase I safety study
P2860
Q22241984-553F7998-AA0B-45F0-AC97-7AD54F6BEEF2Q25255777-E51481F7-162D-45C6-B897-1F7028B495C0Q27319762-1A038050-C6C7-4D0D-9C08-DD577316EBF6Q27860698-CFC83759-C7C5-430C-8F5E-B1233FC9375FQ28347291-FAF7AEF4-B2FE-47AC-AACD-358B7AE42F49Q28469094-FCB012DA-F6A9-4675-A6F1-4BC9EF67B213Q28475576-067266C7-0E49-4BB8-93C9-9499AB110EC9Q28728736-7040028E-9ABB-454B-92C3-40F45FC28A46Q28754733-15143AD3-8001-4E4C-8ED3-0084E1058604Q28972526-195061C3-C5F9-4E74-96EE-827AEBA788DFQ31146636-A2157883-F259-46FF-B41D-97C8EFE82B90Q33631238-B307AFD1-4CFE-44AB-8DF7-3213CDFC3089Q33676594-8AD150EE-E398-45AC-9A48-1E2994A74DBAQ33799700-5C97528B-AC46-4BE7-B9CE-A446603F5186Q33803446-71D7B467-D27C-4151-B837-784D1B8F852EQ33805975-5828BF45-0237-4314-8A2F-FC5BEC96979BQ33835126-69875FB6-29C0-4061-92C7-5C565A51D052Q33836117-E8867ABE-310E-43A8-8AA7-D973370E96CCQ33842771-3C952642-20F6-4481-8215-F753F0731431Q33843340-6ED1592F-7144-478F-91CA-0FF020D9CDBEQ33843388-9DF38631-16D1-4428-974D-55FA6014F3A5Q33845018-A1326DC0-3E24-4F75-80CB-9564B5962997Q33850510-FCE350ED-AA9B-465B-B533-A40D0F0B74FEQ33852947-564DE134-060B-4990-AD0B-1027E41F2621Q33874266-79B1FF1E-EC9C-41EA-B4DE-49E8DA463010Q33880339-C6427909-8752-4BF4-966C-57C6BF1D57F6Q33931464-39C8C50B-8CE5-4B34-AE95-661BEA7613EEQ33936926-089EF35A-62EF-4624-82EB-137E344362DEQ33949316-8285E8CA-C023-4B46-8C28-8473A7CB9D2AQ33980046-1F948EAC-7D51-45C0-9E0E-57F0B3C984DFQ33998262-C6E4C4B3-53B9-409F-835D-57992ECFBB54Q34143945-035E39A8-5AEC-45FB-8776-57C1E46DBDE9Q34143960-CCA39CEE-C36E-47F2-9A27-BBDAB826FAA0Q34178412-6CE3979C-920B-451A-AF39-5DC030A9ABA9Q34218827-1FB8EC23-E7D5-4795-9A8D-D2DB9B5E9F59Q34270951-76FA5CAC-DDEB-404F-92A5-DCFF60F78C41Q34326482-A36EC07F-0B52-4580-A8E4-CA62A6AB6954Q34332462-2FA3B532-9501-46D3-AFAA-2D9748DCDEB6Q34602206-14BFBCBB-76F6-45AB-A0CA-D6C7FA3CBA68Q34711266-B11B5AD7-4841-4770-A2D7-525F4C6871AF
P2860
Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Levels of human immunodeficien ...... active antiretroviral therapy.
@en
Levels of human immunodeficien ...... active antiretroviral therapy.
@nl
type
label
Levels of human immunodeficien ...... active antiretroviral therapy.
@en
Levels of human immunodeficien ...... active antiretroviral therapy.
@nl
prefLabel
Levels of human immunodeficien ...... active antiretroviral therapy.
@en
Levels of human immunodeficien ...... active antiretroviral therapy.
@nl
P2093
P2860
P921
P1433
P1476
Levels of human immunodeficien ...... active antiretroviral therapy.
@en
P2093
A K Trocha
B D Walker
P J Goulder
S A Kalams
P2860
P304
P407
P577
1999-08-01T00:00:00Z